Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle

Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs. Doctors are getting letters from insurance investigators discouraging new prescriptions. And pharmacies are being told by insurers to check for a specific diagnosis when filling prescriptions.

It’s a charge on all fronts by insurance companies to contain the spiraling costs of a new class of weight loss-inducing drugs, the GLP-1s.

Some of these treatments — like Novo Nordisk’s Wegovy — are approved for obesity, while others — like Novo’s Ozempic and Eli Lilly’s Mounjaro — are approved for diabetes, but they all employ similar mechanisms and have exploded in demand for their ability to curb appetite and cut significant amounts of weight.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In